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Abstract
A retrospective cohort analysis of survival after keratinocyte cancer (KC) was conducted using 
data from a large, population-based case control study of KC in New Hampshire. The original 
study collected detailed information during personal interviews between 1993-2002 from 
individuals with squamous (SCC) and basal (BCC) cell carcinoma, and controls identified through 
the Department of Transportation, frequency-matched on age and sex. Participants without a 
history of non-skin cancer at enrolment were followed as a retrospective cohort to assess survival 
after either SCC or BCC, or a reference date for controls. Through 2009, cancers were identified 
from the New Hampshire State Cancer Registry and self-report; death information was obtained 
from state death certificate files and the National Death Index. There were significant differences 
in survival between those with SCC, BCC and controls (p=0.040), with significantly greater risk 
of mortality after SCC compared to controls (adjusted hazard ratio [HR] 1.25; 95% confidence 
interval 1.01-1.54). Mortality after BCC was not significantly altered (HR 0.96; 95% CI 
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0.77-1.19). The excess mortality after SCC persisted after adjustment for numerous personal risk 
factors including time-varying non-skin cancer occurrence, age, sex and smoking. Survival from 
the date of the intervening cancer, however, did not vary (HR for SCC 0.98; 95% CI 0.70-1.38). 
Mortality also remained elevated when individuals with subsequent melanoma were excluded (HR 
for SCC 1.30; 95% CI 1.05-1.61). Increased mortality after SCC cannot be explained by the 
occurrence of intervening cancers, but may reflect a more general predisposition to life threatening 
illness that merits further investigation.
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BACKGROUND
Each year in the United States, between one and 3.5 million keratinocyte cancers (KC) are 
diagnosed, consisting primarily of basal cell (BCC) and squamous cell carcinoma (SCC).12 
In some populations, the incidence of KC has tripled over the past 30 years 3 resulting in 
substantial morbidity and treatment expense. KC, and particularly BCC, rarely metastasize 
and although their treatment may present substantial challenges, they are generally curable. 
There is an increased incidence of other cancers among individuals with KC,4-25 but it is 
unclear whether this is due to an individual’s susceptibility to cancer, environmental 
exposures, or a combination of factors. There are also indications of reduced relative 
survival after KC, particularly after SCC, but the studies that have examined this in detail 
provide mixed results.2126-33 Population-based data suggest that the 5-year relative survival 
rates (RSR) after BCC are close to 100%, and some estimates even suggest that BCC is 
associated with better survival than population controls.27 In contrast, 5 year RSR after SCC 
is closer to 90%, but the reason for these effects is unclear.532
We previously studied risk factors for KC in a large, population-based case control study of 
individuals with incident BCC or SCC and controls, using a combination of detailed 
personal risk factor data. Subsequent cancers were examined in a retrospective cohort 
analysis of the same individuals, having ascertained cancers and deaths via linkage to the 
state cancer registry and national and state death certificate records. In that study, the risk of 
subsequent cancer was significantly raised after BCC (HR 1.40; 95% CI 1.15 to 1.71) and 
modestly raised after SCC (HR 1.18; 95% CI 0.95 to 1.46).25 Here, we present mortality 
data from the same cohort.
MATERIAL AND METHODS
Ethics Statement
This work was approved by the Committee for the Protection of Human Subjects of 
Dartmouth College (#21177). Participants in the New Hampshire Skin Cancer Study 
(NHSCS) underwent an informed consent process at enrolment. Use of data from the New 
Hampshire State Cancer Registry was approved by the New Hampshire Department of 
Public Health Services. The analytic dataset was de-identified to protect confidentiality.
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New Hampshire Skin Cancer Study
The New Hampshire Skin Cancer Study is described in detail elsewhere.34 Population-based 
surveillance was conducted for keratinocyte cancers (KC) newly diagnosed between 1993 
and 2002 among New Hampshire residents, and participants were recruited for a case 
control study. The reference date for the study was defined as the date of diagnosis, or a 
matched comparable date generated for controls. Data collection occurred in three phases, 
with refinement of the variables collected in each phase. Personal interviews were conducted 
with 2,713 individuals with KC (SCC 1,170; BCC 1,543), and 1,416 controls frequency 
matched on age and sex; information was collected on a variety of health, behavior and 
environmental exposures. This follow-up analysis is based on a sample size that was 
determined according to the goals of the original case control study.
New Hampshire State Cancer Registry
The New Hampshire State Cancer Registry (NHSCR) is a population-based registry of 
reportable incident cancers covering the ~1.2 million residents of New Hampshire. Data 
from 1995 onwards meet the North American Association of Central Cancer Registries 
standards for quality and completeness.35 Data from 1986-1995 are partially complete, and 
some information is available on cases diagnosed before 1986 and in other states. Deaths are 
identified through annual linkage with state death certificates and the National Death Index.
Exclusions of individuals with a prior history of cancer
Participants were excluded from the mortality analyses if, before the reference date, they had 
a diagnosis of cancer other than KC or melanoma that had been identified either through 
NHSCR or self-report at study enrolment. Self-reports of major cancers have previously 
been shown to be fairly reliable 3637 and were likely to provide an accurate diagnosis in 
cases that may not have been identified through NHSCR i.e., if they occurred outside New 
Hampshire or before 1995. To maximize consistency between self-reported and registry 
cancers, we considered in situ malignancies (excluding cervix and prostate) in NHSCR as 
“prior” cancers.
Ascertainment of cancer and death following KC
We linked the NHSCS database with NHSCR to identify incident cancers through 2009, 
using definitions of reportable cancers from 2008.38 Invasive cancers were defined as those 
of stage 1 or higher, or bladder cancers of any stage (including in situ, stage 0). In addition, 
we obtained self-reported cancer data via a mailed survey to all participants who were not 
known to have died. This survey collected information on cancer diagnosis and cancer site, 
date, treating hospital or other facility, and the type of treatment given; self-reported cancers 
that had not been confirmed by NHSCR were adjudicated by one investigator (JR) and 
determined to be “confirmed” or “unconfirmed”. We linked the NHSCS database with 
NHSCR and with the New Hampshire death certificate database for the period 1993-2009 
and with the National Death Index (NDI) through December 31, 2009 to identify deaths 
nationwide. Analyses of disease-specific mortality were based on the underlying cause of 
death determined from death certificates. The underlying cause is identified from conditions 
reported in the medical certification section of the death certificate using an algorithm of 
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selection rules standardized by the World Health Organization and implemented in the 
Automated Classification of Medical Entities system.3940
Statistical analysis
The endpoint for our primary analyses was the time from the reference date to either death 
or to December 31st, 2009. We used Cox proportional hazard models to estimate hazard 
ratios (HRs) and 95% confidence intervals (CI) associated with mortality for BCC and SCC 
cases (separately) versus controls. For all analyses, except where stated, the HRs were 
adjusted for age, sex, and smoking (in pack-years: 0, 0.l-20, 20.1-40, >40). To investigate 
the effects of subsequent diagnosis of cancer on survival we first stratified by subsequent 
cancer status and performed interaction tests to evaluate the effects of subsequent cancer on 
group differences (BCC, SCC and control). We then determined the overall differences 
between BCC, SCC and control groups by fitting subsequent cancer as a time-varying 
factor. Proportional hazards assumptions were tested by observation of the survival curves 
and using a global test based on the Schoenfeld residuals.
In secondary analyses, we similarly assessed mortality in the subgroups of participants with 
and without a subsequent melanoma. In a subgroup analysis of those with a subsequent 
cancer, we assessed survival dated from the diagnosis of that cancer. Finally, we performed 
sensitivity analyses to assess the effect of including cancer cases only identified through 
death certificates (“death certificate only”, or DCO).
All analyses were conducted using Stata v11.
RESULTS
Of the 4,223 individuals enrolled in the case control study, 639 were excluded because of a 
prior non skin cancer at the time of enrolment leaving 3,584 individuals for analysis (Table 
1). Adjusted models included between 3,407 and 3,584 individuals due to missing covariate 
data.
During an average of >10 years of observation, 587 eligible participants had subsequent 
reportable cancer and 561 participants died with or without subsequent cancer (Table 1). 
Overall, there were significant differences in mortality between the three case groups 
(controls, BCC, SCC) after adjustment for age, sex, smoking and subsequent cancer (time-
varying), with poorer survival after SCC relative to controls than after BCC relative to 
controls (Table 2, Figure 1). Specifically, a statistically significantly higher mortality was 
seen among individuals with SCC compared to controls (HR 1.25; 95% CI 1.01 to 1.54). 
Mortality among those with BCC was not statistically significantly different than controls. 
In sensitivity analyses, exclusion of in situ cancers did not materially alter the findings (data 
not shown).
In the same model, subsequent cancer was independently associated with survival, after 
adjusting for age, sex, and case group (HR 2.58; 95% CI 2.16 to 3.09) and this association 
did not appear to differ between case groups (p for interaction = 0.95) (Table 2 and Figure 
1). When time-varying subsequent cancer status was excluded from the model, the relative 
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differences in mortality seen by case group were essentially unchanged (data not shown), 
and the mortality associated with SCC remained high (HR 1.24; 95% CI 1.01 to 1.53). 
Survival measured from the date of subsequent cancer diagnosis, instead of the date of KC 
diagnosis, did not differ significantly between groups. In particular, survival after SCC in 
this subgroup analysis was similar to that in controls (HR 0.98; 95% CI 0.70 to 1.38).
Analyses of survival after a subsequent melanoma were conducted without adjustment for 
age, sex or smoking due to the small numbers of participants (N=89). Among those who 
developed a melanoma after the reference date, those with KC did so substantially earlier 
than controls (BCC 265 days; 95% CI 233 to 298, and SCC 1044 days; 95% CI 1010 to 
1079). Compared to controls, there was poorer survival among individuals with a 
subsequent melanoma in the SCC group (crude HR 1.29; 95% CI 0.26 to 6.44) and in the 
BCC group (crude HR 1.16; 95% CI 0.25 to 5.38), but overall, the difference between the 
three case groups did not achieve statistical significance (p=0.36). Among those without a 
subsequent melanoma (N=3,316), the patterns of survival in the case groups were similar to 
those seen in all participants (p=0.026), with an increased mortality risk after SCC (HR 1.30; 
95% CI 1.05 to 1.61) but not after BCC (HR 0.99; 95% CI 0.80 to 1.24).
Several factors were independently related to survival (Supplementary Table 1). Higher 
mortality was associated with increasing age, male sex and current smoking, with a three-to 
four-fold increased risk in those with a 40+ pack year smoking history. No clear pattern was 
observed with level of education or body mass index.
The most common subsequent cancers identified in the cohort were of prostate, melanoma, 
breast, lung and colon (Supplementary Table 2). After KC, 15% of individuals (n=59) 
experienced two or more subsequent cancers during the observation period compared with 
only 7% (n=14) controls.
The survival probabilities, after adjustment for age, sex and smoking, reflected the relative 
trend in survival across groups (control>BCC>SCC) for those with and without subsequent 
cancer and the clearly poorer survival among those with subsequent cancer (Figure 1). Death 
certificates most commonly attributed death to cancer among those who had a confirmed 
subsequent cancer (with lung cancer being the most common of these), and cardiovascular/
respiratory causes among those who did not (Supplementary Table 3).
When we conducted sensitivity analyses (not shown) to assess the impact on our results of 
inclusion of “death certificate only” cancers (i.e. those not confirmed by medical records, 
N=17), our results were essentially unchanged.
DISCUSSION
Our results indicate differences in survival among individuals with SCC, BCC and controls 
during an average of more than 10 years of follow-up. Those with SCC had 25% higher 
mortality risk than controls after adjusting for age, sex, pack-years of smoking and time-
varying subsequent cancer occurrence. The adjusted hazard ratio for mortality after BCC vs 
controls was close to 1 despite a 40% higher risk of intervening cancer,25 indicating that 
there may be important differences between the major histologic types of KC with respect to 
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survival.25 A series of Danish studies also identified survival differences between SCC and 
BCC, with mortality 29 to 61% higher after SCC and 3 to 11% lower after BCC.26-29 
Finnish data from the 1960s and 1970s indicated relative survival rates close to 100% for 
BCC at 5 and 10 years; and for SCC, 90% at 5 years and 83-87% at 10 years.32 These, and 
our own data indicate that future studies of cancer and mortality after KC should report BCC 
and SCC separately as analyses that pool these two distinct histologies are likely to be 
uninterpretable.
Our findings suggest that the increased mortality after SCC cannot be explained by 
subsequent cancer. Although SCC was independently associated with increased mortality, 
adjustment for time-varying subsequent cancer status in the multivariable model did not 
materially reduce the excess mortality after SCC. Moreover, the excess mortality after SCC 
cannot be explained by mortality from cutaneous SCC itself as this is infrequently fatal.41 
Mortality after SCC also remained substantially elevated even after excluding individuals 
with subsequent melanoma. It is possible that individuals with SCC are at greater risk of 
developing other diseases that reduce life expectancy; all of our models adjusted for 
smoking and we assessed other risk factors, but other lifestyle factors may have contributed. 
For example, the Danish studies identified an excess of deaths due to diseases linked to 
smoking, alcohol and immune suppression.26-28 We did not have the statistical power to 
assess these questions in our study. We cannot yet provide new targets to clinicians for 
prevention strategies, but our results highlight the need to identify more specifically the 
genetic and behavioral risk factors for mortality in SCC patients that may offer new 
opportunities for prevention.
Another possible explanation for increased mortality after SCC is a tendency to experience 
subsequent cancers with a worse prognosis; several studies have reported substantially 
higher mortality after cancer when individuals have a prior SCC 3042-44 or BCC 21 43. Our 
findings do not support those observations; among those who developed a subsequent 
cancer, we found no evidence of a difference between case groups in survival measured 
from the subsequent cancer diagnosis. In contrast, Hjalgrim reported that non Hodgkin’s 
lymphoma was associated with 51% higher mortality after BCC and 75% higher after SCC, 
and that a more recent SCC was associated with worse prognosis 43. Brauer found that 
metastases from melanoma were more likely in individuals with a prior KC (odds ratio 2.89; 
95% CI 1.33 to 6.26), and among those with a metastasis, a history of KC increased the risk 
of early (versus late) metastasis (OR 4.83; 95% CI 1.04 to 22.39)45. In colorectal cancer, 
lymph node involvement at the time of diagnosis was more likely in individuals with a 
history of KC than in those without.46 Nugent could not explain the increased mortality after 
KC in breast and colorectal cancer in terms of differences in stage21, and others have not 
provided evidence that cancers were diagnosed at a more advanced stage after SCC.214748 
Although we did not observe any differences in mortality following cancer among KC 
patients, we had a limited ability to assess specific cancers, and stage at diagnosis and site- 
and stage-specific mortality for subsequent cancers. Further, a shorter interval between 
diagnoses of KC and subsequent cancer might be expected if increased medical surveillance 
associated with a KC diagnosis leads to earlier identification of a subsequent cancer; but if 
that were true, we would expect a better prognosis. It is possible that potentially toxic 
modalities such as radiotherapy might lead to subsequent morbidity and mortality; however, 
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SCC is infrequently treated with radiation. In an academic hospital-based cohort study, 
initial treatment of SCC involved radiotherapy in fewer than 4% of cases. 41 It is likely that 
the proportion receiving radiotherapy in our cohort would have been even lower than 4%, 
because a hospital-based cohort would include a higher proportion of more complex cases 
referred for specialist treatment.
Limitations of this study include the possibility of misclassification of cancer diagnoses and 
deaths as a result of inaccuracies in the cancer registry and death databases, or due to the 
linkage algorithms. In addition to lack of statistical power, lack of confidence in the ability 
of death certificates to provide accurate cause of death data4950 prevented an effective 
assessment of cause of death in our cohort. We did not identify new diagnoses of 
keratinocyte cancers during follow-up; undocumented changes in case group (e.g controls 
becoming cases) might lead to a conservative bias in our results. Power limited our ability to 
assess mortality following specific cancers, and to assess stage at diagnosis and site- and 
stage-specific mortality for subsequent cancers. Lastly, our findings are based on a cohort 
from northern New England, which experiences extreme seasonal weather; our ability to 
generalize these findings to other populations thus cannot be certain.
In conclusion, in our cohort of individuals with SCC, BCC and age and sex-matched 
controls with detailed exposure and medical history data, we identified increased mortality 
after SCC, but not BCC, which does not appear to be attributable to the increased frequency 
of other cancers after keratinocyte cancer. It will be important to identify more specific risk 
factors for mortality after SCC for future preventive strategies to address this issue.
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Keratinocyte cancers are rarely fatal but are associated with increased risk of subsequent 
cancer and mortality for reasons that are unclear. During >10 years’ follow-up, we 
identified a 25% increased mortality after SCC compared with controls, but mortality in 
those with BCC was unaffected. Despite examining a wide range of personal risk factor 
data, we could not explain the excess mortality in terms of intervening non-skin cancers, 
melanoma, smoking, or other personal characteristics.
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Survival curves after keratinocyte cancer for participants with subsequent cancer, without 
subsequent cancer, and all
Total with subsequent cancer (N=542) does not equal 587 due to missing covariate data
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